Trial Profile
A Randomized, Double-blind, Placebo and Active-controlled, Multicenter, Parallel-group Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg to Evaluate Efficacy, Safety and Pharmacokinetics in Patients With Mild to Moderate Essential Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Losartan
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 08 Nov 2010 New trial record
- 30 Sep 2010 Results were presented at the 23rd Scientific Meeting of the International Society of Hypertension.